The purpose of this chapter is to support and educate myeloma patients about new immunotherapies that are obtaining FDA approval or those that are still in clinical trials. This chapter will include discussion about CAR T therapy, antibody drug conjugates, bispecific antibodies, trispecific antibodies, vaccines, NK cell approaches and more.